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Abstract: Aspergillus oryzae and A. flavus are important species in industrial 
biotechnology and food safety and have been some of the first aspergilli to be fully genome 
sequenced. Bioinformatic analysis has revealed 99.5% gene homology between the two 
species pointing towards a large coherence in the secondary metabolite production. In this 
study we report on the first comparison of secondary metabolite production between the 
full genome sequenced strains of A. oryzae (RIB40) and A. flavus (NRRL 3357). 
Surprisingly, the overall chemical profiles of the two strains were mostly very different 
across 15 growth conditions. Contrary to previous studies we found the aflatrem precursor 
13-desoxypaxilline to be a major metabolite from A. oryzae under certain growth 
conditions. For the first time, we additionally report A. oryzae to produce parasiticolide A 
and two new analogues hereof, along with four new alkaloids related to the A. flavus 
metabolites ditryptophenalines and miyakamides. Generally the secondary metabolite 
capability of A. oryzae presents several novel end products likely to result from the 
domestication process from A. flavus. 
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1. Introduction 
Aspergillus oryzae is one of industry’s most used “workhorses” and has been used for centuries in 
food fermentation for the production of e.g., sake, soy sauce and other traditional Asian foods [1].  
A. oryzae is also a widely used organism for production of amylase, lipases and proteases and more 
recently also for heterologous expression of secondary metabolite genes and non-fungal proteins [2–4]. 
For many years, A. oryzae has been suspected to be a domesticated form of A. flavus, a plant and 
mammalian pathogenic saprophyte, capable of producing some of the most carcinogenic compounds 
known: the aflatoxins. Genetic work and subsequent genome sequencing of strains of both species 
have verified the tight link between the species [1,5–8]. 
The relationship of the two species has resulted in extensive screening of the toxic potential of  
A. oryzae, but no genuine evidence of aflatoxin production in validated A. oryzae isolates has ever 
been shown. Other important toxins, known from A. flavus, have on the other hand been shown in  
A. oryzae: 3-Nitropropionic acid [9] and cyclopiazonic acid (CPA) [10] along with kojic acid [11,12] 
(Figure 1). Additional metabolites previously reported from A. oryzae are asperfuran [13], sporogen 
AO1 [14,15], maltoryzine [16], and aspergillomarasmine A [17,18]. Aspirochlorine has been found in 
A. flavus, A. oryzae and A. tamarii [19–23] (Figure 1). For reviews on the safety and taxonomy of  
A. oryzae, see [7,24–26]. 
Figure 1. Known compounds from Aspergillus flavus or A. oryzae. 
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The few predicted differences between the genomes of A. oryzae and A. flavus (ca. 99.5% genome 
homology and 98% at the protein level for RIB40/ATCC 42149 and NRRL 3357 [27]), could lead one 
to expect A. oryzae to produce most of the metabolites found in A. flavus [1,28–31], but published 
metabolic data indicates a very low chemical correlation [32]. It is with reference to the established 
genetic heritage of A. oryzae from A. flavus remarkable that maltoryzine, sporogen AO1, asperfuran 
and aspergillomarasmine A have never been unambigously identified in A. flavus. Though research on 
A. flavus chemistry has focused primarily on toxic compounds, one would expect that these 
metabolites should be part of its chemical potential as they are for the domesticated A. oryzae. The 
preliminary bioinformatic studies in conjunction with the genome sequencing shows roughly the same 
number of predicted genes: 32 Polyketide synthases (PKSs) and 28 non-ribosomal synthases (NRPSs) 
for A. flavus and 32 PKSs and 27 NRPSs for A. oryzae with 2 NRPSs apparently unique for each  
strain [33]. The exclusiveness of these genes in terms of end product has yet to be verified chemically. 
Most of the predicted genes for secondary metabolites of A. oryzae (or A. flavus) have not been 
mapped to specific metabolic products, despite the genome sequencing of RIB40 in 2005 [27]. Only 
genes of the most important toxins: Aflatoxin [31,34,35], CPA [36,37] and aflatrem [38] have been 
fully annotated in both species, which leaves much to be explored. The full chemical potential of either 
species is unknown and epigenetic modifiers [39–43] may be necessary, alongside with the use of 
different growth conditions to aid triggering the full potential of secondary metabolite expression in 
these two closely related species. 
The aim of the current work has been to perform an initial comparative investigation of the 
chemistry from the two genome sequenced strains of A. oryzae (RIB40) and A. flavus (NRRL 3357), in 
order to get further insights into possible homologies and differences in secondary metabolite 
production for these two important species. 
2. Results and Discussion 
2.1. De-Replication of A. oryzae RIB40 
For the analysis of A. oryzae RIB40 chemistry, we investigated a series of solid media (YES, 
YESBEE, DRYES, CYA, CYAS, CY20, CY40, DUL, GAK, GMMS, MEA, OAT, PDA, TGY, 
WATM (see Methods and Materials for explanation) cultivations with micro-scale extractions [44,45] 
and subsequently analyzed with HPLC-DAD-MS for selection of optimal conditions. The different 
media were tested on a collection of A. oryzae (RIB40, IBT 28103) and A. flavus (NRRL 3357, IBT 
23106, IBT 3642) and these strains were cultivated at 25 °C in the dark for 7 and 14 days. The media 
screening for A. oryzae and A. flavus indicated the greatest chemodiversity and metabolite production 
from CYA, YES and WATM agar for our purpose. 
The comparison of the secondary metabolite profiles of the two strains, NRRL 3357 and RIB40, 
exposed a surprisingly high degree of chemical difference on all media as illustrated in Figure 2 and 
Table 1 for the WATM medium. The major metabolite repetitions between the two genome sequenced 
strains were merely kojic acid and ergosterol, like a number of minor metabolites (not analyzed here) 
seemed to be shared between the two strains. Altogether, this is in sharp contrast to the high gene 
homology, particularly for the secondary metabolite genes. 
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Figure 2. ESI+ BPC chromatogram of 7 day micro scale extract from WATM, bottom:  
A. oryzae RIB40, top: A. flavus NRRL 3357. Besides kojic acid (shown in box) and analogues 
in the beginning of chromatogram and ergosterol in the end (not shown), there are very few 
identical compounds between the genetically almost identical strains. Note that aspirochlorine 
is only detectable in negative ionization, and therefore not visible in this chromatogram. 
 
Table 1. LC-MS de-replication of some of the important secondary metabolite pathways 
from the two full genome sequenced siblings, A. flavus (NRRL 3357) and A. oryzae 
(RIB40). Based on 7 day fermentation on solid WATM agar in the dark. (+) indicates the 
presence of these types of compounds in A. flavus based on UV spectroscopic analysis.  
* New compounds reported here for the first time. 
Metabolite A. flavus NRRL 3357 A. oryzae RIB40 
Kojic acid + + 
Aflatoxin + - 
Aflavinines (+) + 
Aflatrem + 13-desoxypaxilline 
Miyakamides (+) Oryzamides * 
Aspirochlorine - + 
Cyclopiazonic acid + - 
Ditryptophenaline + Ditryptoleucine * 
Parasiticolide A - 14-deacetyl parasiticolide A * 
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Known metabolites to A. oryzae were de-replicated and we found that the RIB40 strain did not 
produce detectable levels (LC-MS) of CPA (as also noted by Tokuoka et al. [36]), asperfuran, 
sporogen AO1, maltoryzine or aspergillomarasmine under these growth conditions. It did, however, 
produce kojic acid and aspirochlorine and a series of potentially new metabolites of which some were 
isolated, structurally characterized and reported here. 
2.2. New Metabolites to A. oryzae RIB40 
During fermentation of the chemically potent RIB40 strain, we have been interested in the 
tremorgenic compounds, allegedly coupled to fungal sclerotia [46–54] and whether these could be 
found in A. oryzae as they have been in A. flavus. The RIB40 strain produces large and abundant 
sclerotia, especially on WATM agar, a fact not widely announced in literature although sclerotia have 
been observed in A. oryzae sporadically [55–57]. No sclerotia were observable after 14 days on YES 
agar, but although these metabolites are often characterized as sclerotial metabolites, there is not a 
strict correlation between the biosynthesis of these metabolites and the formation of sclerotia, as also 
noted by Wilson [58], and this extract was used for the described isolations. 
Here, we report the discovery of the aflatrem precursor 13-desoxypaxilline (13-dehydroxypaxilline) 
in A. oryzae RIB40, originally isolated from Penicillium paxilli [59–63]. Aflatrem is known from  
A. flavus and was discovered by Wilson and Wilson in 1964 [64] and structure elucidated by  
Gallagher et al. in 1978 and 1980 [65,66]. 13-desoxypaxilline was present in YES, CYA, OAT and 
WATM agar 7 day old micro-scale extracts. From the 14 days old YES 200 plate extract used for 
isolation, 13-desoxypaxilline was recovered as an intermediate metabolite. LC-MS, LC-MS/MS and 
NMR data analysis (Supplementary Material) confirmed the structure. Naturally the prospect of 
finding aflatrem itself was investigated, though no apparent peak was visible in HPLC-DAD data files. 
The use of a LC-MS/MS method further confirmed 13-desoxypaxilline as an end-product of A. oryzae 
RIB40 for the above cultivation conditions, since none of the proposed intermediate steps towards 
aflatrem could be detected (LC-MS/MS) and only one sample (WATM, 7d) showed traces of 
paspaline, a precursor for 13-desoxypaxilline (Figure 3). 
Figure 3. The final steps in the proposed biosynthesis of aflatrem (in A. flavus). A. oryzae 
RIB40 biosynthesis stops at 13-desoxypaxilline [38]. 
 
Metabolites 2012, 2              
 
 
44
A second extract was made from 100 plates of a 14-day old A. oryzae RIB40 culture grown on 
WATM agar with abundant sclerotia formation to validate the findings from the YES extract. The 
analysis of the WATM extract showed 13-desoxypaxilline as a major metabolite alongside other 
sclerotium-related metabolites, such as aflavinines (based on UV-data not shown). The discovery of 
13-desoxypaxilline as the apparent end-product of A. oryzae RIB40 is in agreement with the analysis 
of Nicholson et al. [38], who showed that a frameshift mutation in the atmQ gene presumably accounts 
for 13-desoxypaxilline not being converted into paspalicine and paspalinine. This mutation is therefore 
likely responsible for terminating the aflatrem biosynthesis in RIB40 prematurely, short of the acetal 
ring closure, C-13 hydroxylation and isoprene attachment. Nicholson et al. [38] demonstrated that 
AtmQ is a multifunctional cytochrome P450 monooxygenase likely to catalyze the several oxidative 
steps needed for biosynthesis of the acetal ring present in the structures of paspalicine, paspalinine and 
aflatrem, altogether pointing towards a more complex biosynthesis than shown here. Contrary to our 
discovery, Nicholson et al. did not find the aflatrem gene cluster of RIB40 to be transcribed during 
their fermentations [38]. 
The isolated 13-desoxypaxilline is a member of the paspalitrem tremorgens, a widely distributed 
group of metabolites that have been isolated from several genera: Penicillium, Eupenicillium, 
Claviceps, Emericella, Aspergillus and Phomopsis [67–69]. Besides the tremorgenic activity in 
animals, these metabolites have been shown to be insecticides [68], which is believed to be their 
ecological function together with aflatoxin and CPA for protection of the sclerotia against fungivorous 
insects [46,47]. 
In addition to 13-desoxypaxilline, two new analogues of parasiticolide A were also isolated and are 
here reported for the first time. The metabolites showed to be dide- and 14-deacetoxy analogues, and 
are most likely precursors to the sesquiterpene parasiticolide A (= astellolide A) (see Figure 4). The 
metabolites were present in CYA, YES and WATM extracts and isolated from the same 14 day old 
YES extract as 13-desoxypaxilline, and the dide- and 14-deacetyl analogues were also found in the 
sclerotia enriched WATM extract. Again the metabolites were analyzed using LC-MS and NMR. 
Several different extraction procedures were tested to verify the correctness of the compounds as 
genuine metabolites and not as in vitro degraded parasiticolide A products, but all samples showed 
only dide- and 14-deacetyl parasiticolide A and no traceable (LC-MS) levels of parasiticolide A itself, 
even with different non-acidic extractions. Parasiticolide A have been isolated from A. flavus var. 
columnaris (FKI-0739) once [71] and was originally isolated and characterized from A. parasiticus 
(IFO 4082) [72,73] and later also from a mutant of Emericella variecolor (= A. stellatus Curzi) [74]. 
Recently parasiticolides have been detected in the newly described species A. arachidicola (CBS 
117610) and A. minisclerotigenes (CBS 117635) [75]. There have to our knowledge not been 
published any toxic studies on the parasiticolides, but the related peniopholides from the fungus 
Peniophora polygonia have been reported to have antifungal properties [76]. 
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Figure 4. Structures of dide- and 14-deacetyl parasiticolide A and parasiticolide A. 
 
In our observations parasiticolides are more often detectable metabolites of A. oryzae than of  
A. flavus under the same fermentation conditions, suggesting that the pathway is partly silenced for  
A. flavus and may need epigenetic modification to be expressed under otherwise normal growth 
conditions. It is interesting that parasiticolide A is scarcely observed in A. flavus, when it is an 
important product of A. oryzae and also of A. parasiticus. As for 13-desoxypaxilline, dide- and  
14-deacetyl parasiticolide A are almost certainly products of a prematurely ended biosynthesis, here 
parasiticolide A. We also isolated and elucidated a third parasiticolide A analogue; a formyl variant of 
parasiticolide A, but it was not possible to exclude the possibility of in vitro chemistry due to the 
formic acid added during the ethyl acetate extraction, so the correctness of this metabolite remains 
tentative. (Hamasaki et al. used benzene to extract parasiticolide A [77]). All paraciticolide analogues 
were structure elucidated by NMR and shift values correlated with the published data for parasiticolide 
A, except for the missing signals of the acetate units and their minor influence on the chemical shifts 
values of adjacent protons and carbons (See Supplementary Material for NMR data). 
To further verify these observations, a MS/MS method was used to analyze several different 
microscale extracts of RIB40 for parasiticolide A itself. Trace amounts of parasiticolide A was found 
under these conditions and compared to an isolate of A. parasiticus (IBT 4387) capable of producing 
parasiticolide A. In the A. parasiticus isolate no dide- or 14-deacetyl parasiticolide A could be 
measured, indicating a complete transformation into the end-product (Figure 4). The small amount of 
parasiticolide A in RIB40 (roughly 1:1.000 ratio compared to 14-acetyl parasiticolide A, presuming the 
same response factor) might be the result of spontaneous acetylation involving the first acetylating 
enzyme. When the gene cluster of this metabolite is mapped, it is likely that the gene responsible for 
the last (specific) acetylation will be found to be mutated. Except for the section Nidulantes member 
Emericella variecolor, all other producers of these metabolites have been members of section Flavi. 
No indication points to these metabolites being part of the previously mentioned sclerotium 
metabolites since they are not found in selective sclerotium extracts, but are found for example in  
A. arachidicola, which is not known to produce sclerotia. 
Four new A. flavus related NRPS compounds were also isolated from A. oryzae RIB40 and 
characterized based on standard interpretation of 1H, COSY, HMQC and HMBC NMR data (see 
Supplementary Material). The compounds showed to be two isomeric metabolites named ditryptoleucine 
related to the ditryptophenalines [78–81] and the two indole-enamides named oryzamides A1-2 (cis- 
and trans-forms) structurally similar to the antibiotic miyakamide B1-2 [71] (Figure 5). 
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Figure 5. Structure of the new A. oryzae metabolites: Ditryptoleucine and oryzamide A1-2. 
 
It proved difficult to unambiguously isolate the cis- and trans-isomer of oryzamide A in a pure form 
due to isomerization around the double bond. Due to this the structure elucidation has been performed 
on mixtures of compounds. It is evident from the structure elucidation that oryzamides A1-2 only differ in 
the configuration around the double bond of the enamine as evident from the size of the coupling constant. 
Marfey analysis of the amino acid derived compounds only established the presence of L-tyrosine in 
the oryzamides. NMR structural data on the trans isomer (A1) is present in the supporting material. 
Intriguingly, these A. oryzae metabolites have apparently exchanged phenylalanine with leucine 
compared to the similar A. flavus metabolites, indicating either a common trait in the domestication 
process or a coupling between the two pathways. The diketopiperazine ditryptoleucine was isolated in 
two variants with 1H-NMR shifts varying around the C-C dimeric bond, but with the same base 
structure. This unspecific dimerization is in line with previously isolated compounds. A hybrid 
between the ditryptophenaline and ditryptoleucine was isolated from an Aspergillus sp. as WIN 64745, 
with both a phenylalanine and leucine moiety, but with no N-methylation [79]. These compounds were 
tested and proved antagonistic against substance P at the NK1 receptor [82]. The oryzamides A1-2 are 
variants of the miyakamides B1-2 [71]. The exchanged phenylalanine has been substituted with leucine 
between a tryptophan and a tyrosine in the oryzamides. However this exchange of phenylalanine and 
leucine has often been found for compounds produced within the same species. Penicillium polonicum 
(= P. fructigenum) [83-85] produces both fructigenine A = puberuline = rugulosuvine A, containing 
phenylalanine and fructigenine B = verrucofortine, containing leucine. We could also detect two 
slightly later eluting compounds in the A. oryzae RIB40 extracts likely to be two further indole-enamides 
having phenylalanine incorporated instead of tyrosine as evident from LC-DAD-MS analysis (data not 
shown) as also seen for the miyakamides [71]. 
3. Experimental 
General procedures and methods for analysis are described in [43,44,86]. 
Mass spectrometric analysis was performed using a Agilent HP 1100 liquid chromatograph with a 
DAD system (Waldbronn, Germany) on a LCT oaTOF mass spectrometer (Micromass, Manchester, 
UK) with a Z-spray ESI source and a LockSpray probe. For general procedures see [87]; method 1 for 
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LC-DAD-TOF was used in this study. All solvents used were HPLC grade from Sigma-Aldrich  
(St. Louis, MO, USA). 
3.1. Fungal Material and Fermentation 
A. oryzae RIB40 (IBT28103); A. flavus NRRL3357 (IBT3696), (IBT15934), NRRL 13462;  
A. parvisclerotigenus IBT16807 and A. minisclerotigenes IBT13353 were obtained from the IBT 
Culture Collection at DTU Systems Biology, Technical University of Denmark. The RIB40 isolate 
used for isolation of 13-dehydroxypaxilline was cultured for 14 days at 25 °C in the dark on 200 Petri 
dishes with Yeast Extract Sucrose agar (YES). All strains were grown for 1 week at 25 °C on YES, 
Czapek Yeast Autolysate (CYA), Wickerhams Antibiotic Test Medium (WATM) agar [88], YESBEE [89] 
(YES+50 g Bee pollen Type III, granulate, Sigma, P-8753, pr. 1 L medium), DRYES (Dichloran rose 
Bengal chloramphenicol agar), AFPA (Aspergillus flavus, A. parasiticus agar), CYAS (CYA + 50 g 
NaCl pr. 1 L medium), CY20 (CYA + 170 g sucrose pr. 1 L), CY40 (CYA with added 370 g sucrose 
pr. 1 L medium), DUL (Dulaney’s medium for Penicillin), GAK (Potato-carrot agar), GMMS (Glucose 
minimal media (GMM) + 2% sorbitol), MEA (Malt extract agar), OAT (Oat meal agar), PDA (Potato-
dextrose agar). For medium formulations see Samson et al. [90]. 
3.2. Extraction and Isolation of Pure Compounds 
13-Desoxypaxilline. The plates were homogenized using a Stomacher and 100 mL EtOAc with 1% 
HCO2H pr. 10 plates. The extract was filtered and dried down on a freeze drier. The crude extract was 
separated on a KP-C18-HS 60 g SNAP column using a Biotage Isolera One (Biotage, Uppsala, 
Sweden), resulting in a 22 mg fraction. The fraction was segmented with a 10 g ISOL Diol column, 
using 12 steps of stepwise Heptane-dichloromethane-EtOAc-MeOH. 13-desoxypaxilline was 
predominant in a 100% EtOAc fraction (6 mg), and purified on a Waters HPLC W600/996PDA 
(Milford, MA, USA) and a RP column (Phenomenex Luna C18(2), 250 × 10 mm, 5 µm, Torrance, CA, 
USA) using a gradient of 80% MeCN (H2O–Milli-Q (Millipore, MA, USA)) to 90% over 10 min. with 
50 ppm TFA added to the solvents. The collection was concentrated on a rotary evaporator (Büchi V-855/ 
R-215, Flawil, Switzerland) and dried under N2 to yield 0.5 mg of white, amorphous 13-desoxypaxilline. 
Dideacetyl-, 14-deacetyl-, and 18-formyl parasiticolide A. From the same fermentation described for 
13-desoxypaxilline a more polar, 90 mg fraction was fractionated with a 10 g ISOL Diol column, using 
12 steps of stepwise Heptane-dichloromethane-EtOAc-MeOH. The parasiticolide A-analogues were 
predominant in a 100% EtOAc fraction (10 mg), and purified on a Waters HPLC W600/996PDA 
(Milford, MA, USA) and a RP column (Phenomenex Luna C18(2), 250 × 10 mm, 5 µm, Torrance, CA, 
USA) using a gradient of 72% MeCN (H2O–Milli-Q (Millipore, MA, USA)) to 87% over 15 min. with 
50 ppm TFA. The collection was concentrated on a rotary evaporator (Büchi V-855/R-215) and dried 
under N2 to yield 0.3, 1.0 and 0.8 mg of white, amorphous di-, 14-deactyl- and 18-formyl 
parasiticolide A, respectively. See Supplemental Material for NMR data. 
Ditryptoleucine. 400 plates of A. oryzae RIB40 were cultured on YES medium. The plates were 
homogenized using a Stomacher and 100 mL EtOAc pr. 10 plates. The extract was filtered and dried 
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down on a freeze drier. The crude extract were separated into three phases by dissolving it in 9:1 
MeOH:H2O–Milli-Q and extracted into a heptan phase and afterwards a DCM phase. The DCM phase 
was separated on a KP-C18-HS SNAP column using a Biotage Isolera One (Biotage, Uppsala, 
Sweden) using a gradient of 10% MeOH (H2O–Milli-Q (Millipore, MA, USA)) to 100% over 15 CVs 
(column volumes) resulting in a 402 mg fraction. The fraction was further separated on another  
KP-C18-HS SNAP column using a Biotage Isolera One (Biotage, Uppsala, Sweden) using a gradient 
of 10% MeOH (H2O–Milli-Q (Millipore, Ma, USA)) to 25% over 2 CVs, 25% MeOH to 50% over 8 
CVs and 50% to 100% over 4 CVs resulting in a 60.1 mg fraction. The fraction was fractionated on a 
LH-20 column using 100% MeOH. The ditryptoleucines were present in the earlier fractions and were 
purified on a Waters HPLC W600/996PDA (Milford, MA, USA) using a RP column (Phenomenex 
Luna C18(2), 250 × 10 mm, 5 µm, Torrance, CA, USA) using a gradient of 50% MeCN (H2O–Milli-Q 
(Millipore, MA, USA)) to 100% over 20 min. with 50 ppm TFA and a flow of 4 mL/min. The 
collections were concentrated on a rotary evaporator (Büchi V-855/R-215) and dried under N2 to yield 
4.0 mg of the two isomers. See Supplemental Data for NMR data. 
Oryzamides A1-2. The remaining broth from the fermentation described for ditryptoleucine was 
extracted with EtOAc + 1% HCO2H for 24 h. The extract was filtered and dried down on a freeze 
drier. The crude extract were separated into three phases by dissolving it in 9:1 MeOH:H2O–Milli-Q 
and extracted into a heptan phase and afterwards a DCM phase. The DCM phase was separated on a  
KP-C18-HS SNAP column using a Biotage Isolera One (Biotage, Uppsala, Sweden) using a gradient 
of 10% MeOH (H2O–Milli-Q (Millipore, MA, USA)) to 100% over 15 CVs (column volumes) 
resulting in a 654 mg fraction. The fraction was fractionated with a 10 g ISOL Diol column, using  
13 steps of stepwise Hexane-dichloromethane-EtOAc-MeOH. The miyakamides were predominant in 
the 40:60 DCM:EtOAc and 20:80 DCM:EtOAc fractions (43.8 mg), and purified on a Waters HPLC 
W600/996PDA (Milford, MA, USA) and a RP column (Phenomenex Luna C18(2), 250 × 10 mm, 
5µm, Torrance, CA, USA) using a gradient of 45% MeCN (H2O–Milli-Q (Millipore, MA, USA)) to 
62% over 15 min. with 50 ppm TFA. The collection was concentrated on a rotarvap (Büchi V-855/ 
R-215) and dried down under N2 to yield 4.0 and 2.0 mg of oryzamide A1 and A2, respectively. See 
Supplemental Data for NMR data. 
3.3. Marfeys Method 
100 µg of each peptide was hydrolysed with 200 µL 6 M HCl at 110 °C for 20 h. To the hydrolysis 
products (or 50 µL (2.5 µmol) solutions of standard D- and L-amino acids) was added 50 µL water,  
20 µL 1 M NaHCO3 solution and 100 µL 1% FDAA in acetone, followed by reaction at 40 °C for 1 h. 
The reaction mixture was removed from the heat, neutralized with 10 µL 2 M HCl and the solution 
was diluted with 820 µL MeOH to a total volume of 1 mL. The FDAA derivatives were analysed by 
UHPLC-DAD on a Dionex Ultimate 3000 RS DAD equipped with a Kinetex C18 column (2.6 μm, 
150 × 2.10mm, Phenomenex). The analyses were run with a gradient elution of MeCN/H2O–Mili-Q 
(Millipore, MA,USA) added 50 ppm TFA from 15 to 100% MeCN over 7 min (60 °C, 0.8 mL/min). 
The retention times of the FDAA derivatives were compared to retention times of the standard amino 
acid derivatives. 
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3.4. Selective Extraction of Sclerotium Metabolites 
The selective extraction of sclerotia from IBT 15934, NRRL 13462, IBT 16807 and IBT 13353 was 
made from harvested sclerotia of a 7 day old cultivation on WATM and CYA agar (25 °C in dark). 
The sclerotia were washed several times with Milli-Q (Millipore, Millford, USA) 0.22 µm H2O and 
dried. The sclerotia were transferred to a 2 mL Eppendorf tube together with three stainless steel balls 
(2 × 1 mm and 1 × 5 mm) and frozen with liquid N2 before mechanical crushed. The pulverized 
sclerotia were suspended in 1mL methanol and transferred to a 2 mL vial with 1 mL of 1:2:3 
methanol:dichloromethane:ethylacetate and left for evaporation overnight in a fume hood. The dried 
extract was resolved in 1 mL methanol in ultrasonicated for 10 min and then filtered with a 0.45 µm 
PTFE filter to a clean vial for analysis. 
3.5. HPLC-DAD-TOF Method 
Mass was measured using a Agilent HP 1100 liquid chromatograph with a DAD system 
(Waldbronn, Germany) on a LCT oaTOF mass spectrometer (Micromass, Manchester, UK) with a  
Z-spray ESI source and a LockSpray probe. For general procedures see [86], method 1. 
3.6. NMR Instrumentation 
NMR spectra were recorded on a Varian Unity Inova 500 MHz spectrometer equipped with a 5 mm 
probe using standard pulse sequences. The signals of the residual solvent protons and solvent carbons 
were used as internal references (δH 2.50 and δC 39.5 ppm for DMSO). In cases where higher field was 
needed the NMR spectra were recorded on a Bruker Avance 800-MHz spectrometer equipped with a 
5-mm TCI Cryoprobe at the Danish Instrument Center for NMR Spectroscopy of Biological 
Macromolecules. 
3.7. MS/MS Method Used for Aflatrem and Parasiticolide Screening 
Liquid chromatography was performed on an Agilent (Torrence, CA, USA) 1100 HPLC system 
coupled to a triple-quadropole mass spectrometer (Waters-Micromass, Manchester, UK) with a Z-spray 
ESI operated in positive mode source using a flow of 700 L/h nitrogen desolvated at 350 °C. The 
hexapole was held at 50 V. The system was controlled by MassLynx v4.1 (Waters-Micromass). 
Nitrogen was used as collision gas, and the MS operated in MRM mode (dwell time = 100 ms) with 
the parameters listed in Table 2. Extracts of 2 µL were injected and separated on a Phenomenex 
Gemini C6-phenyl, 3 µm, 2 × 50 mm column with a flow of 0.3 µL/min. Water contained 20 mM 
ammonium formate. Oven temperature 40 °C. Two different methods were applied to the aflatrem- and 
parasiticolide screen: Aflatrem inlet method: Linearly gradient from 50 to 100% MeCN over 5 min, 
increased to 0.5 µL/min over 1.5 min. The column was washed additionally 1.5 min with 100% MeCN at 
0.5 µL/min, followed by a return to 50% MeCN over 2.5 min and kept at this level for another 1 min 
with a linearly decrease in flow to 0.3 µL/min, prior to the next sample. Standards used for analysis of 
this pathway were from Sigma-Aldrich Aldrich (St. Louis, MO, USA). Parasiticolides: linearly gradient 
from 20 to 90% MeCN over 15 min, increased to 0.5µL/min from 90 to 100% MeCN in additional  
1 min. The column was washed from 2 min with 100% MeCN at 0.5 µL/min, followed by a return to 
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20% MeCN over 1.5 min and kept at this level for another 3.5 min with a linearly decrease in flow to  
0.3 µL/min, before the next sample. Standards were internal standards from other extracts of the known 
parasiticolide A producer A. parasiticus: IBT 4387 (= CBS 260.67) and IBT 11863 (= CBS 115.37). 
Table 2. MS/MS method including scan event, retention times, transition ions and the cone 
and collision energies used. 
Compound Scan 
event 
RT 
(min) 
Ion type Transition 
(m/z) a 
Cone 
(V) 
Collision energy 
(eV) 
Paxilline 1 4.0 Quantifier 
Qualifier 
436 → 130 
436 → 182 
25 
25 
30 
30 
Paspalinine 2 4.3 Quantifier 
Qualifier 
434 → 130 
434 → 376 
25 
25 
20 
20 
13-
desoxypaxilline 
3 4.8 Quantifier 
Qualifier 
420 → 182 
420 → 130 
25 
25 
30 
30 
Aflatrem 4 5.2 Quantifier 
Qualifier 
502 → 198 
502 → 445 
25 
25 
20 
20 
Paspaline 5 5.5 Quantifier 
Qualifier 
422 → 130 
422 → 275 
25 
25 
20 
20 
Dideacetyl-
parasiticolide A 
1 7.0 Quantifier 
Qualifier 
387 → 217 
387 → 189 
30 
30 
40 
40 
14-deacetyl 
parasiticolide A 
2 8.7 Quantifier 
Qualifier 
429 → 217 
429 → 189 
30 
30 
40 
40 
Parasiticolide A 3 10.4 Quantifier 
Qualifier 
488 → 229 
488 → 247 
30 
30 
30 
30 
a All transitions were made from [M+H]+, except for paraciticolide A: [M+NH4]+. 
4. Conclusions 
The tremorgenic 13-desoxypaxilline has been isolated from A. oryzae RIB40 and verified under 
several different growth conditions contrary to previous studies. We believe that 13-desoxypaxilline is 
the end-product of the aflatrem biosynthesis for the RIB40 strain since no aflatrem could be detected in 
any fermentation using LC-MS/MS as detection. 
The new metabolites dide- and 14-deacetyl parasiticolide A were also found as genuine products 
from the RIB40 strain and the compounds were present in multiple fermentations, however 
parasiticolide A was only detected in trace amounts using a LC-MS/MS method. This indicates a 
defective acetylation of the 14-deacetyl parasiticolide A and the small amount of parasiticolide A in 
RIB40 could be the result of spontaneous acetylation in the cell cytosol. The mono-deacetylated analogue 
detected in both A. flavus and A. oryzae had same retention times, suggesting a selective acetylation. 
The new NRPS compounds ditryptoleucine and oryzamides A1-2 appear to be natural variants of 
known A. flavus metabolites. They share the exchange of a phenylalanine for a leucine, although they 
are believed to originate from two unrelated pathways. 
Altogether, our findings contribute to understanding why the overall chemical profiles of A. oryzae 
(RIB40) and A. flavus (NRRL 3357) appear quite different since some of the end-products usually seen 
in A. flavus are apparently not reached in A. oryzae. Whether the different chemical profiles are merely 
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the result of different regulation that can be overcome by the use of epigenetic modifiers or are a result 
of genuine mutations remains to be settled. A. oryzae RIB40 is clearly a chemically potent strain, and 
as more of its chemistry is unfolded we believe that most of the biosynthetic pathways of A. flavus will 
be found to be more or less functional. Future research will reveal whether the many different  
A. oryzae strains that are used as industrial workhorses are as chemically potent as the RIB40 strain. 
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